NSVGF
Price
$0.01
Change
-$0.01 (-50.00%)
Updated
Nov 13 closing price
Capitalization
4.72M
SHPMY
Price
$8.29
Change
+$0.30 (+3.75%)
Updated
Feb 21 closing price
Capitalization
9.5B
Ad is loading...

NSVGF vs SHPMY

Header iconNSVGF vs SHPMY Comparison
Open Charts NSVGF vs SHPMYBanner chart's image
Nass Vy Gateway
Price$0.01
Change-$0.01 (-50.00%)
Volume$29.75K
Capitalization4.72M
Shanghai Pharmaceuticals Holdings
Price$8.29
Change+$0.30 (+3.75%)
Volume$301
Capitalization9.5B
NSVGF vs SHPMY Comparison Chart
Loading...
View a ticker or compare two or three
VS
NSVGF vs. SHPMY commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NSVGF is a Hold and SHPMY is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (NSVGF: $0.01 vs. SHPMY: $7.99)
Brand notoriety: NSVGF and SHPMY are both not notable
Both companies represent the Medical Distributors industry
Current volume relative to the 65-day Moving Average: NSVGF: 100% vs. SHPMY: 18%
Market capitalization -- NSVGF: $4.72M vs. SHPMY: $9.5B
NSVGF [@Medical Distributors] is valued at $4.72M. SHPMY’s [@Medical Distributors] market capitalization is $9.5B. The market cap for tickers in the [@Medical Distributors] industry ranges from $70.55B to $0. The average market capitalization across the [@Medical Distributors] industry is $9.87B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NSVGF’s FA Score shows that 0 FA rating(s) are green whileSHPMY’s FA Score has 0 green FA rating(s).

  • NSVGF’s FA Score: 0 green, 5 red.
  • SHPMY’s FA Score: 0 green, 5 red.
According to our system of comparison, SHPMY is a better buy in the long-term than NSVGF.

Price Growth

NSVGF (@Medical Distributors) experienced а 0.00% price change this week, while SHPMY (@Medical Distributors) price change was +8.41% for the same time period.

The average weekly price growth across all stocks in the @Medical Distributors industry was -0.50%. For the same industry, the average monthly price growth was -0.93%, and the average quarterly price growth was +1.71%.

Industries' Descriptions

@Medical Distributors (-0.50% weekly)

Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.

FUNDAMENTALS
Fundamentals
SHPMY($9.5B) has a higher market cap than NSVGF($4.72M). NSVGF YTD gains are higher at: 0.000 vs. SHPMY (-4.139). SHPMY has higher annual earnings (EBITDA): 11.1B vs. NSVGF (-1.57M). SHPMY has higher revenues than NSVGF: SHPMY (241B) vs NSVGF (29.5K).
NSVGFSHPMYNSVGF / SHPMY
Capitalization4.72M9.5B0%
EBITDA-1.57M11.1B-0%
Gain YTD0.000-4.139-
P/E RatioN/A8.39-
Revenue29.5K241B0%
Total Cash0N/A-
Total Debt1.24MN/A-
FUNDAMENTALS RATINGS
SHPMY: Fundamental Ratings
SHPMY
OUTLOOK RATING
1..100
51
VALUATION
overvalued / fair valued / undervalued
1..100
40
Fair valued
PROFIT vs RISK RATING
1..100
97
SMR RATING
1..100
81
PRICE GROWTH RATING
1..100
50
P/E GROWTH RATING
1..100
37
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

NSVGF and

Correlation & Price change

A.I.dvisor tells us that NSVGF and PDRX have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NSVGF and PDRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NSVGF
1D Price
Change %
NSVGF100%
N/A
PDRX - NSVGF
8%
Poorly correlated
N/A
SHPMY - NSVGF
4%
Poorly correlated
+3.10%
SHTDF - NSVGF
4%
Poorly correlated
N/A
MAHLY - NSVGF
2%
Poorly correlated
+0.73%
AMFPF - NSVGF
0%
Poorly correlated
N/A
More

SHPMY and

Correlation & Price change

A.I.dvisor tells us that SHPMY and PDRX have been poorly correlated (+8% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SHPMY and PDRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SHPMY
1D Price
Change %
SHPMY100%
+3.10%
PDRX - SHPMY
8%
Poorly correlated
N/A
ZYXI - SHPMY
5%
Poorly correlated
+1.59%
NSVGF - SHPMY
4%
Poorly correlated
N/A
SHTDF - SHPMY
3%
Poorly correlated
N/A
MEPDF - SHPMY
-3%
Poorly correlated
N/A
More